Value through InnovationSeptember 30 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim press releases. To quickly find all press releases on a specific topic, please use the search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10
09.27.2014

Head-to-head Phase III trial demonstrates superior progression-free survival of afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung

09.27.2014

Boehringer Ingelheim’s afatinib achieves primary endpoint in global Phase III study in recurrent/metastatic head and neck squamous cell cancer

09.26.2014

Statement on FDA Drug Development Public Meeting for Idiopathic Pulmonary Fibrosis (IPF)

- For U.S. Media Only
09.25.2014

Boehringer Ingelheim Announces FDA Approval of Spiriva® Respimat® (tiotropium bromide) Inhalation Spray for the Maintenance Treatment of COPD

- For U.S. Media
09.18.2014

Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy

- For U.S. Media
09.16.2014

Boehringer Ingelheim Named to Working Mother’s “100 Best Companies for Working Mothers” List

09.10.2014

European Commission grants Lilly and Boehringer Ingelheim’s insulin glargine product marketing authorisation in Europe

- For U.S. Media Only
09.10.2014

To Mark Pulmonary Fibrosis Awareness Month, Boehringer Ingelheim Announces Discovery Channel Documentary on Idiopathic Pulmonary Fibrosis

09.09.2014

New Analysis of Phase III Trials Examines the Impact of Boehringer Ingelheim’s IPF Therapy Nintedanib on Lung Function Decline Based on Patients’ Baseline Severity

- For U.S. Media Only
09.08.2014

Boehringer Ingelheim Presents Pivotal Phase III Data for the Investigational Fixed-Dose Combination of Tiotropium + Olodaterol in COPD

- For U.S. Media Only
back 1 2 3 4 5 6 7 8 9 10